CGRP Education & Research Forum
Already a member? Login Become a member Register
  • Home
  • About Us
    • About CGRP Forum
    • Editorial Board
  • About CGRP
    • About CGRP
    • CGRP and migraine
    • Unmet needs in migraine prevention
    • What is the role of CGRP in migraine?
    • Why is CGRP an important therapeutic target?
    • Migraine is a complex neurovascular condition
  • News
    • News
    • Meeting Reports
    • Real World Experience
  • Newsletter
  • Hot Topics
  • Videos
    • Meet the Expert: Issues and Answers
  • Trials
    • Atogepant (AGN-241689)
    • Erenumab (AMG 334)
    • Eptinezumab (ALD403)
    • Galcanezumab (LY2951742)
    • Fremanezumab (TEV-48125)
    • Rimegepant (BHV-3000)
    • Ubrogepant (MK-1602)
  • Resources
    • CGRP in the Journals
    • Meetings
    • Backgrounders
    • Slides
    • Links
    • Videos
  • Contact US
Hot off the press: New Forum launches
twitterfacebookyoutubeLinkedIn
Latest:
EU approval for Vydura (rimegepant) in acute and preventive migraine treatmentRimegepant linked to reduced opioid prescriptions and medication overuse headacheAtogepant attenuates activation of Aδ- and C-fibre meningeal nociceptorsPatients advised to start ubrogepant as soon as migraine headache startsAtogepant associated with decrease in body weightFour or fewer monthly headache days proposed as treatment goal for chronic migraineFremanezumab efficacy and disability benefits following onabotulinumtoxinA treatment failureDRAGON data confirm erenumab efficacy and safety in chronic migraine in Asia
Previous image
Next image

slide04

15 November 2016 Full size 630 × 232

Post navigation

Published inUnmet needs in migraine prevention

Trials

  • Atogepant (AGN-241689)
  • Erenumab (AMG 334)
  • Galcanezumab (LY2951742)
  • Fremanezumab (TEV-48125)
  • Eptinezumab (ALD403)
  • Rimegepant (BHV-3000)
  • Ubrogepant (MK-1602)

Meeting Reports

  • American Academy of Neurology 2022
  • XXV World Congress of Neurology 2021
  • International Headache Congress 2021
  • 7th Congress of the European Academy of Neurology
  • 63rd Annual Meeting of the American Headache Society
  • American Academy of Neurology 2021 Virtual Annual Meeting
  • Migraine Trust International Symposium 2020
  • 14th European Headache Federation Congress
  • 62nd Annual Meeting of the American Headache Society
  • 6th Congress of the European Academy of Neurology
  • American Academy of Neurology 2020
  • World Congress of Neurology 2019
  • IHC 2019
  • American Headache Society (AHS) 61st Annual Scientific Meeting
  • 5th Congress of the European Academy of Neurology
  • 13th European Headache Federation Congress
  • American Academy of Neurology Annual Meeting 2019
  • 12th European Headache Federation Congress
  • 17th Biennial Migraine Trust International Symposium
  • American Headache Society (AHS) 60th Annual Scientific Meeting
  • 4th Congress of the European Academy of Neurology
  • American Academy of Neurology (AAN) Congress
  • 11th European Headache Federation Congress
  • 18th Congress of the International Headache Society
  • American Headache Society Annual Scientific Meeting
  • 3rd Congress of the European Academy of Neurology
  • American Academy of Neurology Annual Meeting
  • Scottsdale Headache Symposium
  • ​​The European Headache and Migraine Trust International Congress (EHMTIC)

Resources

  • Slides
    • Migraine care in Brazil: the role of anti-CGRP therapies
    • Atogepant
    • Erenumab
    • Eptinezumab
  • Meetings
  • Links
Invite a colleague »

Educational Partners and Supporters (others pending) Amgen
Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Partnership & OutreachThrough its unique global network of researchers and clinicians, the CGRP Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of the burden, disability and cost associated with migraine.




© 2022 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |
MENU
  • Home
  • About Us
    • About CGRP Forum
    • Editorial Board
  • About CGRP
    • About CGRP
    • CGRP and migraine
    • Unmet needs in migraine prevention
    • What is the role of CGRP in migraine?
    • Why is CGRP an important therapeutic target?
    • Migraine is a complex neurovascular condition
  • News
    • News
    • Meeting Reports
    • Real World Experience
  • Newsletter
  • Hot Topics
  • Videos
    • Meet the Expert: Issues and Answers
  • Trials
    • Atogepant (AGN-241689)
    • Erenumab (AMG 334)
    • Eptinezumab (ALD403)
    • Galcanezumab (LY2951742)
    • Fremanezumab (TEV-48125)
    • Rimegepant (BHV-3000)
    • Ubrogepant (MK-1602)
  • Resources
    • CGRP in the Journals
    • Meetings
    • Backgrounders
    • Slides
    • Links
    • Videos
  • Contact US